PERAN PENGAWAS MINUM OBAT SEBAGAI INDIKATOR KEBERHASILAN PENGOBATAN TB PADA PASIEN KO-INFEKSI TB - HIV DI RSUD DOK II JAYAPURA PERIODE JANUARI 2011- SEPTEMBER 2012
DOI:
https://doi.org/10.30595/pji.v11i2.827Abstract
ABSTRAK Papua sebagai daerah yang memiliki angka prevalensi HIV-AIDS tertinggi di Indonesia akan menghadapi infeksi Tuberculosis (TB) sebagai infeksi oportunistik terbanyak yang menyerang pasien HIV-AIDS. Keberhasilan dari pengobatan TB adalah bagaimana pasien bisa menghadapi efek samping FDC (Fixed Drug Combination) sehingga pasien tuntas meminum obat tersebut selama 6-8 bulan. Tujuan penelitian yang telah dilakukan ini untuk mengetahui faktor yang mungkin menyebabkan kegagalan pasien TB- HIV selama mendapatkan pengobatan OAT (Obat Anti Tuberkulose) di VCT RSUD Dok II Jayapura selama periode Januari 2011 sampai September 2012. Metode yang dilakukan pada penelitian ini merupakan penelitian retrospektif deskriptif dan data diambil dari rekam medik, kartu TB 01 dan hasil mikrobiologis pasien dengan rentang waktu Januari 2011 sampai dengan September 2012 dimana subjek penelitian adalah pasien koinfeksi TB HIV yang mengambil OAT di VCT RSUD Dok II Jayapura. Hasil yang diperoleh bahwa efek samping obat TB menjadi salah satu kendala selama pengobatan TB sehingga peranan PMO (Pengawas Minum Obat) yang berasal dari keluarga inti mampu membantu pasien menyelesaikan pengobatan TB tersebut. Dari jumlah 124 sampel yang diambil ternyata 35 pasien adalah pasien default yang mengalami efek samping obat dan tidak memiliki PMO. Kata kunci: koinfeksi TB-HIV, efek samping, pengawas minum obat. ABSTRACT Papua as the highest HIV-AIDS prevalence region in Indonesia will be against Tuberculosis (TB) as opportunistic infection of the majority of patients with HIV-AIDS. The success of the treatment is determined by how the patients handle the side effects of FDC (Fixed Drug Combination) successfully during taking the drug for 6-8 months. This study was aimed to find out some influenced factors leading to fail treatment for HIV-AIDS patients after getting FDC (Fixed Dose Combination) drug, from Januari 2011 to September 2012. The retrospective descriptive method was taken to collect data from the medical records, TB- 01 form, and the microbiological testing for TB patients from January 2011 to September 2012. Descriptive study from medical record of 124 TB-HIV coinfection patients in RS Dok II Jayapura, Papua in January 2011 – September 2012 resulted that 35 of 124 patients represented as default patients and they did not have someone as treatment observer because they wanted to keep their HIV status. Patient who has someone from the core family as observer treatment can complete TB treatment and getting help in through all the side effect of FDC drug. Key words: coinfection TB-HIV, side effect, treatment observer.References
Depkes RI, 2000. Pedoman Penyakit Tuberkulosis dan Penanggulangannya. Cetakan ke-7. Jakarta: Depkes RI.
Depkes RI, 2002. ARRIME Pedoman Manajemen Puskesmas Upaya Kesehatan Keluarga Mandiri. Proyek Kesehatan dan Gizi. Jakarta: Depkes RI.
Depkes RI. 2005. Pedoman Penanggulangan Tuberkulosis. Cetakan ke-9. Jakarta: Depkes RI.
Depkes RI. 2012. Profil Kesehatan Indonesia. Jakarta: Depkes RI.
Diedrich, C.R. dan Flynn, J.L. 2011. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis. Infection and Immunity, 79(4): 1407–1417.
Fiske, C.T., Griffin, M.R., Erin, H., Warkentin, J., Lisa, K., Arbogast, P.G., Sterling, T.R., 2010. Black race, sex, and extrapulmonary tuberculosis. BMC Infectious Disease, 10:16.
Kipp, A.M., Stout, J.E. Hamilton, C.D., dan Van Rie, A. 2008. Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993-2006. BMC Public Health, 8:107.
Purwanta, 2005. Ciri-ciri pengawas minum obat yang diharapkan oleh penderita tuberkulosis paru di daerah urban dan rural. JMPK, 08(03).
Soepandi, P.Z., 2008. Diagnosis dan faktor yang mempengaruhi terjadinya TB-MDR. Jakarta: Departemen Pulmonologi & Ilmu kedokteran Respirasi FKUI-RS Persahabatan.
Syaumaryadi, 2001. Hubungan keluhan efek samping obat anti tuberkulosis dengan ketidakpatuhan berobat penderita TB paru di Kota Palembang tahun 1999-2000. Program Pasca Sarjana Ilmu Epidemiologi Kekhususan Epidemiologi Lapangan, Fakultas Kesehatan Masyarakat, Universitas Indonesia.
Tulak, A., Hudoyo, A., Aditama, T.Y. 1999. Pengobatan TBMDR dengan ofloksasin. Tuberkulosis Indonesia. 4:4-8.
Ai, X., Men, K., Guo, L., Zhang, T., Zhao, Y., Sun, X., Zhang, H., He, G., J van der Werf, M., van den Hof, S. 2010. Factors associated with low cure rate of tuberculosis in remote poor areas of Shaanxi Province, China: a case control study. BMC Public Health, 10:112.
WHO, 2011. Combating tuberculosis, principle for accelarating dots coverage. New Delhi: WHO.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
